Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients

Purpose. Comparison of the effects of one year treatment with sibutramine compared to placebo on body weight, glycemic control, lipid profile, and insulin resistance parameters in type 2 diabetic patients. Methods. Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in ther...

Full description

Bibliographic Details
Main Authors: Giuseppe Derosa, Pamela Maffioli, Ilaria Ferrari, Ilaria Palumbo, Sabrina Randazzo, Angela D'Angelo, Arrigo FG Cicero
Format: Article
Language:English
Published: Frontiers Media S.A. 2010-09-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8262
_version_ 1827161926953598976
author Giuseppe Derosa
Pamela Maffioli
Ilaria Ferrari
Ilaria Palumbo
Sabrina Randazzo
Angela D'Angelo
Arrigo FG Cicero
author_facet Giuseppe Derosa
Pamela Maffioli
Ilaria Ferrari
Ilaria Palumbo
Sabrina Randazzo
Angela D'Angelo
Arrigo FG Cicero
author_sort Giuseppe Derosa
collection DOAJ
description Purpose. Comparison of the effects of one year treatment with sibutramine compared to placebo on body weight, glycemic control, lipid profile, and insulin resistance parameters in type 2 diabetic patients. Methods. Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP). Results. We observed a faster improvement of HbA1c, FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups. Conclusions. Sibutramine gave a faster improvement of glycemic control, and of insulin resistance parameters compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.
first_indexed 2024-03-12T07:45:49Z
format Article
id doaj.art-71911b0c934045e3abc70bfcf011dcb0
institution Directory Open Access Journal
issn 1482-1826
language English
last_indexed 2025-03-21T00:36:41Z
publishDate 2010-09-01
publisher Frontiers Media S.A.
record_format Article
series Journal of Pharmacy & Pharmaceutical Sciences
spelling doaj.art-71911b0c934045e3abc70bfcf011dcb02024-08-03T06:40:33ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262010-09-0113310.18433/J3388PEffects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic PatientsGiuseppe DerosaPamela MaffioliIlaria FerrariIlaria PalumboSabrina RandazzoAngela D'AngeloArrigo FG CiceroPurpose. Comparison of the effects of one year treatment with sibutramine compared to placebo on body weight, glycemic control, lipid profile, and insulin resistance parameters in type 2 diabetic patients. Methods. Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP). Results. We observed a faster improvement of HbA1c, FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups. Conclusions. Sibutramine gave a faster improvement of glycemic control, and of insulin resistance parameters compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8262
spellingShingle Giuseppe Derosa
Pamela Maffioli
Ilaria Ferrari
Ilaria Palumbo
Sabrina Randazzo
Angela D'Angelo
Arrigo FG Cicero
Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
Journal of Pharmacy & Pharmaceutical Sciences
title Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
title_full Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
title_fullStr Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
title_full_unstemmed Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
title_short Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients
title_sort effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/8262
work_keys_str_mv AT giuseppederosa effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT pamelamaffioli effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT ilariaferrari effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT ilariapalumbo effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT sabrinarandazzo effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT angeladangelo effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients
AT arrigofgcicero effectsofoneyeartreatmentofsibutramineoninsulinresistanceparametersintype2diabeticpatients